The effects of vitamin D3 supplementation on TGF-β and IL-17 serum levels in migraineurs: post hoc analysis of a randomized clinical trial

Table 2 Changes in serum levels of Treg/Th17 related cytokines before and after supplementation with vitamin D or placebo in episodic migraine patients

Variable	Vitamin D Group (n = 38)		Placebo Group (n = 36)		P-value
Variable	Baseline	After 12 Weeks	Baseline	After 12 Weeks	P-value
Serum TGF-β (ng/L)
Mean (SD)	1308.75 (382.13)	1623.14 (533.81)	1415.56 (312.24)	1445.86 (424.77)	0.123 ^a
Adjusted Mean (95%CI) ^b		1665.50 (1505.95–1825.05)		1361.90 (1191.37–1532.43)	0.012 ^c
serum IL-17 (ng/L)
Mean (SD)	44.21 (67.68)	46.20 (77.32)	66.71 (86.95)	74.99 (85.51)	0.133 ^a
Adjusted Mean (95%CI) ^b		37.84 (17.27–58.41)		70.09 (48.08–92.10)	0.039 ^c

P value < 0.05 was considered significant
^aIndependent sample t-test
^b After 12 Weeks
^cANCOVA test adjusted for baseline levels, age, sex, body mass index (BMI) change, the years having headache, and time from last attack

ISSN: 2055-0294